Encysive, Barr in patent row over Argatroban

01/2/2008 | CNNMoney

Encysive Pharmaceuticals' patent for Argatroban, an injectable blood-clotting treatment, is under challenge. Barr Pharmaceuticals claims its generic version of Argatroban would infringe an existing patent, but contends that Encysive's patent is invalid. Last week, Encysive announced it was trying to keep Barr from obtaining FDA approval for the generic version for 30 months.

View Full Article in:

CNNMoney

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI